Over nine hundred companies across the globe are currently involved in cell and gene therapy and this has been increasing year on year, making it a high growth, high value market. The rising prevalence of chronic diseases and cancer have been some of the key driving factors of this rapid growth. Over the past few years there have been significant and promising developments; the first two commercially available CAR T-cell therapy products (Novartis’ Kymriah and Gilead’s Yescarta) were approved in […]